December 11, 2015
GOSSYPIN AS A NOVEL SELECTIVE DUAL INHIBITOR OF V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1 AND CYCLIN-DEPENDENT KINASE 4 FOR MELANOMA
Mutation in the BRAF gene (BRAFV600E) exists in nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful in early clinical trials. However, in patients with the normal BRAF allele... Read More
